The Biologics Patent Cliff: Inside Pharma’s 2026-2029 Reckoning
A four-year window will reshape biopharma: ten blockbuster biologics worth $136B in annual revenue face biosimilar competition between 2026 and 2029.
Shajini
Lilly’s Quiet $21B Sprint: Seven Deals, One Strategy Hiding in Plain Sight
While the industry debated whether GLP-1 mania had peaked, Eli Lilly closed seven acquisitions in 134 days.
EU Critical Medicines Act Fights Dangerous Supply Crisis
The EU’s Critical Medicines Act takes direct aim at the supply chain vulnerabilities that leave patients without essential drugs when it matters most.
February 2026 Deal Report: Five Signals from $53B in Activity
February 2026 recorded 218 biopharma transactions totalling $53B in disclosed value.
Lilly to buy Ventyx for $1.2B, bolstering oral inflammation pipeline
Lilly acquires Ventyx to expand oral inflammation pipeline.
Lilly taps InduPro’s proximity-guided platform in up to $950M oncology deal
Eli Lilly and Company has entered a global strategic collaboration, licensing agreement, and equity investment with InduPro Therapeutics, betting up to $950 million on a proximity-guided approach to discover first-in-class bispecific and multispecific oncology therapeutics. Under the agreement, the companies will collaborate on up to three oncology targets, with Lilly also taking an equity stake … Read more
Neuropulse Daily: January 8, 2026
Lilly in Advanced Talks to Acquire Ventyx Biosciences in Deal Valued Over $1B Pulse: Compass Pathways Partners With Radial to Shape Psilocybin Care Delivery Pulse: Bial Launches KYNMOBI in the UK for Parkinson’s OFF Episodes Pulse: NeuraLight Completes Landmark Parkinson’s Biomarker Trial Pulse: EA Pharma Initiates Phase 3 Evenamide Trial in Schizophrenia Pulse: Rapport Therapeutics … Read more
Lilly in advanced talks to buy Ventyx in a deal topping $1B
Eli Lilly is in advanced talks to acquire Ventyx Biosciences for more than $1B, a move that would add inflammatory bowel disease and neurology assets.
Lilly Reups With Nimbus in $1.3B Oral Obesity Deal
Eli Lilly has signed a new collaboration with Nimbus Therapeutics worth up to $1.3B to develop a novel oral obesity drug.
NeuroPulse Daily January 7, 2026
VB Spine Completes Acquisition of Stryker’s Cestas Manufacturing Facility Pulse: Anavex Receives Constructive FDA Feedback on Alzheimer’s Disease Program Pulse: Newleos Therapeutics Doses First Patient in Phase 2 SOAR Study for Social Anxiety Disorder Pulse: Lysoway Therapeutics Advances LW-1017 to Phase I Readiness in Neurodegeneration Pulse: LoQus23 Nominates LQT-23 as First-in-Class Oral Drug Candidate for … Read more